1
|
Cebadera Miranda E, Castillo Ruiz-Cabello MV, Cámara Hurtado M. Food biopharmaceuticals as part of a sustainable bioeconomy: Edible vaccines case study. N Biotechnol 2020; 59:74-79. [PMID: 32688060 DOI: 10.1016/j.nbt.2020.06.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 06/22/2020] [Accepted: 06/25/2020] [Indexed: 12/21/2022]
Abstract
The lack of immunization in developing countries is undoubtedly the most serious consequence of the difficulty in accessing traditional vaccination systems. The World Health Organization (WHO) has aimed to find low-cost vaccines, which are accessible to the population and are easy to store and distribute without the need for refrigeration. There is literature support that orally administered edible vaccines are promising agents to reduce the incidence of diseases such as hepatitis and diarrhoea, especially in the developing world. This article focuses on the study of the suitability of edible vaccines as biopharmaceuticals in the context of the 2030 Agenda for Sustainable Development, allowing to comprehensively address both malnutrition and the degree of immunization, mainly in the child population in developing countries. This is embedded within the scope of a new concept promulgated by the UN and FAO called' Therapeutic Food' or 'Ready to Use Therapeutic Food'. Biopharmaceuticals such as edible processed vaccines have the potential to play an important role in increasing global health to achieve the 2030 - Sustainable Development Goals (SDGs), and beyond, as a solution to the dual problem of malnutrition and immunoprophylaxis as part of a sustainable bioeconomy. This article reviews their most promising applications, as well as the problems of a scientific and socioeconomic nature, including the complex current legislation that restricts their implementation.
Collapse
Affiliation(s)
- Elena Cebadera Miranda
- Nutrition and Food Science Department, Pharmacy Faculty, Complutense University of Madrid (UCM), Plaza Ramón y Cajal, s/n, E-28040, Madrid, Spain
| | - Mª Victoria Castillo Ruiz-Cabello
- Nutrition and Food Science Department, Pharmacy Faculty, Complutense University of Madrid (UCM), Plaza Ramón y Cajal, s/n, E-28040, Madrid, Spain
| | - Montaña Cámara Hurtado
- Nutrition and Food Science Department, Pharmacy Faculty, Complutense University of Madrid (UCM), Plaza Ramón y Cajal, s/n, E-28040, Madrid, Spain.
| |
Collapse
|
2
|
Sahoo A, Mandal AK, Dwivedi K, Kumar V. A cross talk between the immunization and edible vaccine: Current challenges and future prospects. Life Sci 2020; 261:118343. [PMID: 32858038 PMCID: PMC7449231 DOI: 10.1016/j.lfs.2020.118343] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 08/12/2020] [Accepted: 08/21/2020] [Indexed: 01/25/2023]
Abstract
INTRODUCTION It is well known that immune system is highly specific to protect the body against various environmental pathogens. The concept of conventional vaccination has overcome the pandemic situation of several infectious diseases outbreak. AREA COVERED The recent idea of immunization through oral route (edible vaccine) is vital alternatives over conventional vaccines. Edible vaccines are composed of antigenic protein introduced into the plant cells which induce these altered plants to produce the encoded protein. Edible vaccine has no way of forming infection and safety is assured as it only composed of antigenic protein and is devoid of pathogenic genes. Edible vaccines have significant role in stimulating mucosal immunity as they come in contact with digestive tract lining. They are safe, cost-effective, easy-to-administer and have reduced manufacturing cost hence have a dramatic impact on health care in developing countries. EXPERT OPINION The edible vaccine might be the solution for the potential hazard associated with the parenteral vaccines. In this review we discuss the detailed study of pros, cons, mechanism of immune stimulation, various outbreaks that might be controlled by edible vaccines with the possible future research and applied application of edible vaccine.
Collapse
Affiliation(s)
- Ankit Sahoo
- Department of Pharmaceutical Science, Shalom Institute of Health and Allied Sciences, Sam Higgbottom University of Agriculture Technology & Sciences, Prayagraj, Uttar Pradesh 211007, India
| | - Ashok Kumar Mandal
- Department of Pharmaceutical Science, Shalom Institute of Health and Allied Sciences, Sam Higgbottom University of Agriculture Technology & Sciences, Prayagraj, Uttar Pradesh 211007, India
| | - Khusbu Dwivedi
- Department of Pharmaceutics, Shambhunath Institute of Pharmacy Jhalwa, Prayagraj, Uttar Pradesh 211015, India
| | - Vikas Kumar
- Natural Product Drug Discovery Laboratory, Department of Pharmaceutical Science, Shalom Institute of Health and Allied Sciences, Sam Higgbottom University of Agriculture Technology & Sciences, Prayagraj, Uttar Pradesh 211007, India.
| |
Collapse
|
3
|
Khan MS, Joyia FA, Mustafa G. Seeds as Economical Production Platform for Recombinant Proteins. Protein Pept Lett 2020; 27:89-104. [DOI: 10.2174/0929866526666191014151237] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 05/13/2019] [Accepted: 08/02/2019] [Indexed: 11/22/2022]
Abstract
:
The cost-effective production of high-quality and biologically active recombinant
molecules especially proteins is extremely desirable. Seed-based recombinant protein production
platforms are considered as superior choice owing to lack of human/animal pathogenic organisms,
lack of cold chain requirements for transportation and long-term storage, easy scalability and
development of edible biopharmaceuticals in plants with objective to be used in purified or partially
processed form is desirable. This review article summarizes the exceptional features of seed-based
biopharming and highlights the needs of exploiting it for commercial purposes. Plant seeds offer a
perfect production platform for high-value molecules of industrial as well as therapeutic nature
owing to lower water contents, high protein storage capacity, weak protease activity and long-term
storage ability at ambient temperature. Exploiting extraordinarily high protein accumulation
potential, vaccine antigens, antibodies and other therapeutic proteins can be stored without effecting
their stability and functionality up to years in seeds. Moreover, ability of direct oral consumption
and post-harvest stabilizing effect of seeds offer unique feature of oral delivery of pharmaceutical
proteins and vaccine antigens for immunization and disease treatment through mucosal as well as
oral route.
Collapse
Affiliation(s)
- Muhammad Sarwar Khan
- Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan
| | - Faiz Ahmad Joyia
- Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan
| | - Ghulam Mustafa
- Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad, Pakistan
| |
Collapse
|
4
|
Plants as sources of natural and recombinant anti-cancer agents. Biotechnol Adv 2018; 36:506-520. [DOI: 10.1016/j.biotechadv.2018.02.002] [Citation(s) in RCA: 89] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 01/23/2018] [Accepted: 02/01/2018] [Indexed: 02/07/2023]
|
5
|
Disease Prevention: An Opportunity to Expand Edible Plant-Based Vaccines? Vaccines (Basel) 2017; 5:vaccines5020014. [PMID: 28556800 PMCID: PMC5492011 DOI: 10.3390/vaccines5020014] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Revised: 05/19/2017] [Accepted: 05/23/2017] [Indexed: 12/17/2022] Open
Abstract
The lethality of infectious diseases has decreased due to the implementation of crucial sanitary procedures such as vaccination. However, the resurgence of pathogenic diseases in different parts of the world has revealed the importance of identifying novel, rapid, and concrete solutions for control and prevention. Edible vaccines pose an interesting alternative that could overcome some of the constraints of traditional vaccines. The term “edible vaccine” refers to the use of edible parts of a plant that has been genetically modified to produce specific components of a particular pathogen to generate protection against a disease. The aim of this review is to present and critically examine “edible vaccines” as an option for global immunization against pathogenic diseases and their outbreaks and to discuss the necessary steps for their production and control and the list of plants that may already be used as edible vaccines. Additionally, this review discusses the required standards and ethical regulations as well as the advantages and disadvantages associated with this powerful biotechnology tool.
Collapse
|
6
|
Makhzoum A, Benyammi R, Moustafa K, Trémouillaux-Guiller J. Recent advances on host plants and expression cassettes' structure and function in plant molecular pharming. BioDrugs 2015; 28:145-59. [PMID: 23959796 PMCID: PMC7100180 DOI: 10.1007/s40259-013-0062-1] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Plant molecular pharming is a promising system to produce important recombinant proteins such as therapeutic antibodies, pharmaceuticals, enzymes, growth factors, and vaccines. The system provides an interesting alternative method to the direct extraction of proteins from inappropriate source material while offering the possibility to overcome problems related to product safety and source availability. Multiple factors including plant hosts, genes of interest, expression vector cassettes, and extraction and purification techniques play important roles in the plant molecular pharming. Plant species, as a biosynthesis platform, are a crucial factor in achieving high yields of recombinant protein in plant. The choice of recombinant gene and its expression strategy is also of great importance in ensuring a high amount of the recombinant proteins. Many studies have been conducted to improve expression, accumulation, and purification of the recombinant protein from molecular pharming systems. Re-engineered vectors and expression cassettes are also pivotal tools in enhancing gene expression at the transcription and translation level, and increasing protein accumulation, stability, retention and targeting of specific organelles. In this review, we report recent advances and strategies of plant molecular pharming while focusing on the choice of plant hosts and the role of some molecular pharming elements and approaches: promoters, codon optimization, signal sequences, and peptides used for upstream design, purification and downstream processing.
Collapse
Affiliation(s)
- Abdullah Makhzoum
- Department of Biology, The University of Western Ontario, London, ON N6A 5B7 Canada
| | - Roukia Benyammi
- Laboratory of Genetic Resources and Biotechnology of the National Superior School of Agronomy, Algiers, Algeria
| | - Khaled Moustafa
- Institut Mondor de la Recherche Biomédicale, Hôpital Henri-Mondor, Créteil, France
| | | |
Collapse
|
7
|
Transgenic barley: a prospective tool for biotechnology and agriculture. Biotechnol Adv 2013; 32:137-57. [PMID: 24084493 DOI: 10.1016/j.biotechadv.2013.09.011] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2013] [Revised: 09/20/2013] [Accepted: 09/24/2013] [Indexed: 11/21/2022]
Abstract
Barley (Hordeum vulgare L.) is one of the founder crops of agriculture, and today it is the fourth most important cereal grain worldwide. Barley is used as malt in brewing and distilling industry, as an additive for animal feed, and as a component of various food and bread for human consumption. Progress in stable genetic transformation of barley ensures a potential for improvement of its agronomic performance or use of barley in various biotechnological and industrial applications. Recently, barley grain has been successfully used in molecular farming as a promising bioreactor adapted for production of human therapeutic proteins or animal vaccines. In addition to development of reliable transformation technologies, an extensive amount of various barley genetic resources and tools such as sequence data, microarrays, genetic maps, and databases has been generated. Current status on barley transformation technologies including gene transfer techniques, targets, and progeny stabilization, recent trials for improvement of agricultural traits and performance of barley, especially in relation to increased biotic and abiotic stress tolerance, and potential use of barley grain as a protein production platform have been reviewed in this study. Overall, barley represents a promising tool for both agricultural and biotechnological transgenic approaches, and is considered an ancient but rediscovered crop as a model industrial platform for molecular farming.
Collapse
|
8
|
Nadal A, Montero M, Company N, Badosa E, Messeguer J, Montesinos L, Montesinos E, Pla M. Constitutive expression of transgenes encoding derivatives of the synthetic antimicrobial peptide BP100: impact on rice host plant fitness. BMC PLANT BIOLOGY 2012; 12:159. [PMID: 22947243 PMCID: PMC3514116 DOI: 10.1186/1471-2229-12-159] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Accepted: 08/07/2012] [Indexed: 05/02/2023]
Abstract
BACKGROUND The Biopeptide BP100 is a synthetic and strongly cationic α-helical undecapeptide with high, specific antibacterial activity against economically important plant-pathogenic bacteria, and very low toxicity. It was selected from a library of synthetic peptides, along with other peptides with activities against relevant bacterial and fungal species. Expression of the BP100 series of peptides in plants is of major interest to establish disease-resistant plants and facilitate molecular farming. Specific challenges were the small length, peptide degradation by plant proteases and toxicity to the host plant. Here we approached the expression of the BP100 peptide series in plants using BP100 as a proof-of-concept. RESULTS Our design considered up to three tandemly arranged BP100 units and peptide accumulation in the endoplasmic reticulum (ER), analyzing five BP100 derivatives. The ER retention sequence did not reduce the antimicrobial activity of chemically synthesized BP100 derivatives, making this strategy possible. Transformation with sequences encoding BP100 derivatives (bp100der) was over ten-fold less efficient than that of the hygromycin phosphotransferase (hptII) transgene. The BP100 direct tandems did not show higher antimicrobial activity than BP100, and genetically modified (GM) plants constitutively expressing them were not viable. In contrast, inverted repeats of BP100, whether or not elongated with a portion of a natural antimicrobial peptide (AMP), had higher antimicrobial activity, and fertile GM rice lines constitutively expressing bp100der were produced. These GM lines had increased resistance to the pathogens Dickeya chrysanthemi and Fusarium verticillioides, and tolerance to oxidative stress, with agronomic performance comparable to untransformed lines. CONCLUSIONS Constitutive expression of transgenes encoding short cationic α-helical synthetic peptides can have a strong negative impact on rice fitness. However, GM plants expressing, for example, BP100 based on inverted repeats, have adequate agronomic performance and resistant phenotypes as a result of a complex equilibrium between bp100der toxicity to plant cells, antimicrobial activity and transgene-derived plant stress response. It is likely that these results can be extended to other peptides with similar characteristics.
Collapse
Affiliation(s)
- Anna Nadal
- Institute of Food and Agricultural Technology (INTEA), University of Girona, Campus Montilivi, EPS-1 17071, Girona, Spain
| | - Maria Montero
- Institute of Food and Agricultural Technology (INTEA), University of Girona, Campus Montilivi, EPS-1 17071, Girona, Spain
| | - Nuri Company
- Institute of Food and Agricultural Technology (INTEA), University of Girona, Campus Montilivi, EPS-1 17071, Girona, Spain
| | - Esther Badosa
- Institute of Food and Agricultural Technology (INTEA), University of Girona, Campus Montilivi, EPS-1 17071, Girona, Spain
| | - Joaquima Messeguer
- Plant Genetics Department, Centre de Recerca en Agrigenòmica CSIC-IRTA-UAB-UB, Carretera de Cabrils, Km 2, 08348, Barcelona, Spain
| | - Laura Montesinos
- Institute of Food and Agricultural Technology (INTEA), University of Girona, Campus Montilivi, EPS-1 17071, Girona, Spain
| | - Emilio Montesinos
- Institute of Food and Agricultural Technology (INTEA), University of Girona, Campus Montilivi, EPS-1 17071, Girona, Spain
| | - Maria Pla
- Institute of Food and Agricultural Technology (INTEA), University of Girona, Campus Montilivi, EPS-1 17071, Girona, Spain
| |
Collapse
|
9
|
Milne R. Pharmaceutical prospects: biopharming and the geography of technological expectations. SOCIAL STUDIES OF SCIENCE 2012; 42:290-306. [PMID: 22849000 DOI: 10.1177/0306312711436266] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The paper explores the role of imagined geographies in the shaping of new technologies. I argue that the role of place in future-oriented visions of technoscience is a neglected topic in studies of the social shaping of technology. The paper proposes an approach that combines the sociology of expectations with the geography of science. It focuses on the interplay between envisaged and current geographies to highlight the recursive dynamics of place and imagination. To illustrate this approach, the paper discusses the example of biopharming, the production of biopharmaceuticals using genetically modified crops. I argue that expectations for biopharming bear the imprint of place, or rather of the places in which they are imagined, as well as those they imagine, and ultimately those they produce. I use this example to suggest how social studies of science and technology can usefully investigate the spaces, places and scales of technological development.
Collapse
Affiliation(s)
- Richard Milne
- Department of Geography, University of Sheffield, Sheffield, UK.
| |
Collapse
|
10
|
Plant-made therapeutics: An emerging platform in South Africa. Biotechnol Adv 2012; 30:449-59. [DOI: 10.1016/j.biotechadv.2011.07.014] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2011] [Revised: 05/26/2011] [Accepted: 07/25/2011] [Indexed: 12/20/2022]
|
11
|
Montesinos E, Badosa E, Cabrefiga J, Planas M, Feliu L, Bardají E. Antimicrobial Peptides for Plant Disease Control. From Discovery to Application. ACS SYMPOSIUM SERIES 2012. [DOI: 10.1021/bk-2012-1095.ch012] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Affiliation(s)
- Emilio Montesinos
- Laboratory of Plant Pathology, Institute of Food and Agricultural Technology-CIDSAV-XaRTA, University of Girona, 17071 Girona, Spain
- LIPPSO, Department of Chemistry; University of Girona, Campus Montilivi, 17071 Girona, Spain
| | - Esther Badosa
- Laboratory of Plant Pathology, Institute of Food and Agricultural Technology-CIDSAV-XaRTA, University of Girona, 17071 Girona, Spain
- LIPPSO, Department of Chemistry; University of Girona, Campus Montilivi, 17071 Girona, Spain
| | - Jordi Cabrefiga
- Laboratory of Plant Pathology, Institute of Food and Agricultural Technology-CIDSAV-XaRTA, University of Girona, 17071 Girona, Spain
- LIPPSO, Department of Chemistry; University of Girona, Campus Montilivi, 17071 Girona, Spain
| | - Marta Planas
- Laboratory of Plant Pathology, Institute of Food and Agricultural Technology-CIDSAV-XaRTA, University of Girona, 17071 Girona, Spain
- LIPPSO, Department of Chemistry; University of Girona, Campus Montilivi, 17071 Girona, Spain
| | - Lidia Feliu
- Laboratory of Plant Pathology, Institute of Food and Agricultural Technology-CIDSAV-XaRTA, University of Girona, 17071 Girona, Spain
- LIPPSO, Department of Chemistry; University of Girona, Campus Montilivi, 17071 Girona, Spain
| | - Eduard Bardají
- Laboratory of Plant Pathology, Institute of Food and Agricultural Technology-CIDSAV-XaRTA, University of Girona, 17071 Girona, Spain
- LIPPSO, Department of Chemistry; University of Girona, Campus Montilivi, 17071 Girona, Spain
| |
Collapse
|
12
|
Dyer GA, González C, Lopera DC. Informal "seed" systems and the management of gene flow in traditional agroecosystems: the case of cassava in Cauca, Colombia. PLoS One 2011; 6:e29067. [PMID: 22174952 PMCID: PMC3236227 DOI: 10.1371/journal.pone.0029067] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2011] [Accepted: 11/20/2011] [Indexed: 11/19/2022] Open
Abstract
Our ability to manage gene flow within traditional agroecosystems and their repercussions requires understanding the biology of crops, including farming practices' role in crop ecology. That these practices' effects on crop population genetics have not been quantified bespeaks lack of an appropriate analytical framework. We use a model that construes seed-management practices as part of a crop's demography to describe the dynamics of cassava (Manihot esculenta Crantz) in Cauca, Colombia. We quantify several management practices for cassava—the first estimates of their kind for a vegetatively-propagated crop—describe their demographic repercussions, and compare them to those of maize, a sexually-reproduced grain crop. We discuss the implications for gene flow, the conservation of cassava diversity, and the biosafety of vegetatively-propagated crops in centers of diversity. Cassava populations are surprisingly open and dynamic: farmers exchange germplasm across localities, particularly improved varieties, and distribute it among neighbors at extremely high rates vis-à-vis maize. This implies that a large portion of cassava populations consists of non-local germplasm, often grown in mixed stands with local varieties. Gene flow from this germplasm into local seed banks and gene pools via pollen has been documented, but its extent remains uncertain. In sum, cassava's biology and vegetative propagation might facilitate pre-release confinement of genetically-modified varieties, as expected, but simultaneously contribute to their diffusion across traditional agroecosystems if released. Genetically-modified cassava is unlikely to displace landraces or compromise their diversity; but rapid diffusion of improved germplasm and subsequent incorporation into cassava landraces, seed banks or wild populations could obstruct the tracking and eradication of deleterious transgenes. Attempts to regulate traditional farming practices to reduce the risks could compromise cassava populations' adaptive potential and ultimately prove ineffectual.
Collapse
Affiliation(s)
- George A Dyer
- The James Hutton Institute, Aberdeen, United Kingdom.
| | | | | |
Collapse
|
13
|
Heinemann JA, Kurenbach B, Quist D. Molecular profiling--a tool for addressing emerging gaps in the comparative risk assessment of GMOs. ENVIRONMENT INTERNATIONAL 2011; 37:1285-93. [PMID: 21624662 DOI: 10.1016/j.envint.2011.05.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/04/2011] [Revised: 04/15/2011] [Accepted: 05/05/2011] [Indexed: 05/20/2023]
Abstract
Assessing the risks of genetically modified organisms (GMOs) is required by both international agreement and domestic legislation. Many view the use of the "omics" tools for profiling classes of molecules as useful in risk assessment, but no consensus has formed on the need or value of these techniques for assessing the risks of all GMOs. In this and many other cases, experts support case-by-case use of molecular profiling techniques for risk assessment. We review the latest research on the applicability and usefulness of molecular profiling techniques for GMO risk assessment. As more and more kinds of GMOs and traits are developed, broader use of molecular profiling in a risk assessment may be required to supplement the comparative approach to risk assessment. The literature-based discussions on the use of profiling appear to have settled on two findings: 1. profiling techniques are reliable and relevant, at least no less so than other techniques used in risk assessment; and 2. although not required routinely, regulators should be aware of when they are needed. The dismissal of routine molecular profiling may be confusing to regulators who then lack guidance on when molecular profiling might be worthwhile. Molecular profiling is an important way to increase confidence in risk assessments if the profiles are properly designed to address relevant risks and are applied at the correct stage of the assessment.
Collapse
Affiliation(s)
- Jack A Heinemann
- School of Biological Sciences, University of Canterbury, Private Bag 4800, Christchurch, New Zealand.
| | | | | |
Collapse
|
14
|
Takaiwa F. Allergen-specific immunotherapy with plant-based oral vaccines. Immunotherapy 2011; 1:517-9. [PMID: 20635982 DOI: 10.2217/imt.09.28] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
15
|
Maffei ME, Gertsch J, Appendino G. Plant volatiles: Production, function and pharmacology. Nat Prod Rep 2011; 28:1359-80. [DOI: 10.1039/c1np00021g] [Citation(s) in RCA: 216] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
16
|
Obembe OO, Popoola JO, Leelavathi S, Reddy SV. Advances in plant molecular farming. Biotechnol Adv 2010; 29:210-22. [PMID: 21115109 DOI: 10.1016/j.biotechadv.2010.11.004] [Citation(s) in RCA: 118] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2010] [Revised: 11/12/2010] [Accepted: 11/12/2010] [Indexed: 01/01/2023]
Abstract
Plant molecular farming (PMF) is a new branch of plant biotechnology, where plants are engineered to produce recombinant pharmaceutical and industrial proteins in large quantities. As an emerging subdivision of the biopharmaceutical industry, PMF is still trying to gain comparable social acceptance as the already established production systems that produce these high valued proteins in microbial, yeast, or mammalian expression systems. This article reviews the various cost-effective technologies and strategies, which are being developed to improve yield and quality of the plant-derived pharmaceuticals, thereby making plant-based production system suitable alternatives to the existing systems. It also attempts to overview the different novel plant-derived pharmaceuticals and non-pharmaceutical protein products that are at various stages of clinical development or commercialization. It then discusses the biosafety and regulatory issues, which are crucial (if strictly adhered to) to eliminating potential health and environmental risks, which in turn is necessary to earning favorable public perception, thus ensuring the success of the industry.
Collapse
Affiliation(s)
- Olawole O Obembe
- Department of Biological Sciences, Covenant University, PMB 1023 Ota, Ogun State, Nigeria.
| | | | | | | |
Collapse
|
17
|
Davies HM. Review article: commercialization of whole-plant systems for biomanufacturing of protein products: evolution and prospects. PLANT BIOTECHNOLOGY JOURNAL 2010; 8:845-861. [PMID: 20731788 DOI: 10.1111/j.1467-7652.2010.00550.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Technology for enabling plants to biomanufacture nonnative proteins in commercially significant quantities has been available for just over 20 years. During that time, the agricultural world has witnessed rapid commercialization and widespread adoption of transgenic crops enhanced for agronomic performance (herbicide-tolerance, insect-resistance), while plant-made pharmaceuticals (PMPs) and plant-made industrial products (PMIPs) have been limited to experimental and small-scale commercial production. This difference in the rate of commercial implementation likely reflects the very different business-development challenges associated with 'product' technologies compared with 'enabling' ('platform') technologies. However, considerable progress has been made in advancing and refining plant-based production of proteins, both technologically and in regard to identifying optimal business prospects. This review summarizes these developments, contrasting today's technologies and prospective applications with those of the industry's formative years, and suggesting how the PM(I)P industry's evolution has generated a very positive outlook for the 'plant-made' paradigm.
Collapse
Affiliation(s)
- H Maelor Davies
- Kentucky Tobacco Research and Development Center, and Department of Plant and Soil Sciences, University of Kentucky, Lexington, KY, USA.
| |
Collapse
|
18
|
Alderborn A, Sundström J, Soeria-Atmadja D, Sandberg M, Andersson HC, Hammerling U. Genetically modified plants for non-food or non-feed purposes: straightforward screening for their appearance in food and feed. Food Chem Toxicol 2009; 48:453-64. [PMID: 20004226 DOI: 10.1016/j.fct.2009.10.049] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2009] [Revised: 10/06/2009] [Accepted: 10/30/2009] [Indexed: 01/17/2023]
Abstract
Genetically modified (GM) plants aimed at producing food/feed are part of regular agriculture in many areas of the World. Commodity plants have also found application as bioreactors, designated non-food/non-feed GM (NFGM) plants, thereby making raw material for further refinement to industrial, diagnostic or pharmaceutical preparations. Many among them may pose health challenge to consumers or livestock animals, if occurring in food/feed. NFGM plants are typically released into the environment, but are grown under special oversight and any among several containment practices, none of which provide full protection against accidental dispersal. Adventitious admixture with food or feed can occur either through distributional mismanagement or as a consequence of gene flow to plant relatives. To facilitate NFGM surveillance we propose a new mandatory tagging of essentially all such plants, prior to cultivation or marketing in the European Union. The suggested tag--Plant-Made Industrial or Pharmaceutical Products Tag (PMIP-T)--is envisaged to occur as a transgenic silent DNA identifier in host plants and designed to enable technically simple identification and characterisation of any NFGM. Implementation of PMIP-T would permit inexpensive, reliable and high-throughput screening for NFGM specifically. The paper outlines key NFGM prospects and challenges as well as the PMIP-T concept.
Collapse
Affiliation(s)
- A Alderborn
- Dept. of Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, SE-75185 Uppsala, Sweden
| | | | | | | | | | | |
Collapse
|
19
|
Karg SR, Kallio PT. The production of biopharmaceuticals in plant systems. Biotechnol Adv 2009; 27:879-894. [PMID: 19647060 DOI: 10.1016/j.biotechadv.2009.07.002] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2009] [Revised: 07/15/2009] [Accepted: 07/17/2009] [Indexed: 12/20/2022]
Abstract
Biopharmaceuticals present the fastest growing segment in the pharmaceutical industry, with an ever widening scope of applications. Whole plants as well as contained plant cell culture systems are being explored for their potential as cheap, safe, and scalable production hosts. The first plant-derived biopharmaceuticals have now reached the clinic. Many biopharmaceuticals are glycoproteins; as the Golgi N-glycosylation machinery of plants differs from the mammalian machinery, the N-glycoforms introduced on plant-produced proteins need to be taken into consideration. Potent systems have been developed to change the plant N-glycoforms to a desired or even superior form compared to the native mammalian N-glycoforms. This review describes the current status of biopharmaceutical production in plants for industrial applications. The recent advances and tools which have been utilized to generate glycoengineered plants are also summarized and compared with the relevant mammalian systems whenever applicable.
Collapse
Affiliation(s)
- Saskia R Karg
- Institute of Microbiology, ETH Zurich, Wolfgang-Pauli Strasse 10, CH-8093 Zürich, Switzerland.
| | - Pauli T Kallio
- Institute of Microbiology, ETH Zurich, Wolfgang-Pauli Strasse 10, CH-8093 Zürich, Switzerland.
| |
Collapse
|
20
|
Sharma AK, Sharma MK. Plants as bioreactors: Recent developments and emerging opportunities. Biotechnol Adv 2009; 27:811-832. [PMID: 19576278 PMCID: PMC7125752 DOI: 10.1016/j.biotechadv.2009.06.004] [Citation(s) in RCA: 112] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2009] [Revised: 06/15/2009] [Accepted: 06/16/2009] [Indexed: 12/18/2022]
Abstract
In recent years, the use of plants as bioreactors has emerged as an exciting area of research and significant advances have created new opportunities. The driving forces behind the rapid growth of plant bioreactors include low production cost, product safety and easy scale up. As the yield and concentration of a product is crucial for commercial viability, several strategies have been developed to boost up protein expression in transgenic plants. Augmenting tissue-specific transcription, elevating transcript stability, tissue-specific targeting, translation optimization and sub-cellular accumulation are some of the strategies employed. Various kinds of products that are currently being produced in plants include vaccine antigens, medical diagnostics proteins, industrial and pharmaceutical proteins, nutritional supplements like minerals, vitamins, carbohydrates and biopolymers. A large number of plant-derived recombinant proteins have reached advanced clinical trials. A few of these products have already been introduced in the market.
Collapse
Affiliation(s)
- Arun K Sharma
- Department of Plant Molecular Biology, University of Delhi South Campus, New Delhi 110021, India.
| | - Manoj K Sharma
- Department of Plant Molecular Biology, University of Delhi South Campus, New Delhi 110021, India
| |
Collapse
|
21
|
Abstract
Plants are attractive expression systems for the economic production of recombinant proteins. Among the different plant-based systems, plant seed is the leading platform and holds several advantages such as high protein yields and stable storage of target proteins. Significant advances in using seeds as bioreactors have occurred in the past decade, which include the first commercialized plant-derived recombinant protein. Here we review the current progress on seeds as bioreactors, with focus on the different food crops as production platforms and comprehensive strategies in optimizing recombinant protein production in seeds.
Collapse
Affiliation(s)
- On Sun Lau
- Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06520-8104, USA; Department of Biology, the Chinese University of Hong Kong, Hong Kong, China
| | - Samuel S M Sun
- Department of Biology, the Chinese University of Hong Kong, Hong Kong, China; State (China) Key Laboratory of Agrobiotechnology (the Chinese University of Hong Kong), Hong Kong China.
| |
Collapse
|
22
|
Sparrow PAC, Twyman RM. Biosafety, risk assessment and regulation of plant-made pharmaceuticals. Methods Mol Biol 2009; 483:341-53. [PMID: 19183909 DOI: 10.1007/978-1-59745-407-0_20] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The technology for plant-made pharmaceuticals (PMPs) has progressed significantly over the last few years, with the first commercial products for human use expected to reach the market by 2009 (see Note 1). As part of the 'next generation' of genetically modified (GM) crops, PMPs will be subject to additional biosafety considerations and are set to challenge the complex and overlapping regulations that currently govern GM plants, plant biologics (see Note 2) and 'conventional' pharmaceutical production. The areas of responsibility are being mapped out between the different regulatory agencies (Sparrow, P.A.C., Irwin, J., Dale, P., Twyman, R.M., and Ma, J.K.C. (2007) Pharma-Planta: Road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Res., 2007), with specific guidelines currently being drawn up for the regulation of PMPs. In this chapter, we provide an overview of the biosafety (see Note 3), risk assessment (see Note 4) and regulation of this emerging technology. While reference will be made to EU regulations, the underlying principles of biosafety and risk assessment are generic to most countries.
Collapse
|
23
|
Basaran P, Rodríguez-Cerezo E. Plant Molecular Farming: Opportunities and Challenges. Crit Rev Biotechnol 2008; 28:153-72. [PMID: 18937106 DOI: 10.1080/07388550802046624] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Frutos R, Denise H, Vivares C, Neuhaus JM, Vitale S, Pedrazzini E, Ma J, Dix P, Gray J, Pezzotti M, Conrad U, Robinson D. Pharmaceutical Proteins in Plants. Ann N Y Acad Sci 2008; 1149:275-80. [DOI: 10.1196/annals.1428.089] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
25
|
Pizzuti F, Daroda L. Investigating recombinant protein exudation from roots of transgenic tobacco. ENVIRONMENTAL BIOSAFETY RESEARCH 2008; 7:219-26. [PMID: 19081009 DOI: 10.1051/ebr:2008020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
It is widely acknowledged that plant-made pharmaceuticals (PMPs) offer numerous benefits, including inexpensive production, biological safety and the facility for production at agricultural scale. At the same time, it is important to minimize any potential risk associated with this new technology, including the potential release of bioactive proteins into the environment. To address this issue, we studied transgenic Nicotiana benthamiana and Nicotiana tabacum plants expressing two recombinant single-chain variable fragment (scFv) antibodies, respectively scFvB9 and scFvH10. ScFvB9 was raised against glycoprotein G1 of Tomato spotted wilt virus (TSWV), and scFvH10 was raised against human tumor-associated antigen tenascin-C. Both antibodies were targeted to the secretory pathway using the N-terminal signal peptide from Phaseolus vulgaris polygalacturonase-inhibiting protein (PGIP), and scFvH10 carried in addition a C-terminal KDEL tetrapeptide for retention in the endoplasmic reticulum (ER). Sterile hydroponic cultures were established, allowing us to investigate whether scFvB9 and scFvH10 were present in root exudates. Intercellular fluids extracted from different plant tissues were analyzed by western blotting revealing the presence of scFvB9. Successful secretion of scFvB9 in hydroponic medium was also demonstrated, whereas no scFvH10 could be detected in the leaf, stem or root apoplast, nor secreted into the hydroponic medium. Our results show that scFvH10 release or diffusion from the roots of transgenic plants was not occurring, suggesting that the KDEL signal might contribute to the environmental biosafety of crops producing PMPs.
Collapse
|
26
|
Cummings JL, Handley LW, Macbryde B, Tupper SK, Werner SJ, Byram ZJ. Dispersal of viable row-crop seeds of commercial agriculture by farmland birds: implication for genetically modified crops. ENVIRONMENTAL BIOSAFETY RESEARCH 2008; 7:241-252. [PMID: 19081011 DOI: 10.1051/ebr:2008021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
To address some concerns about the expansion of genetically engineered pharmaceutical and industrial crops to outdoor plantings and potential impacts on the human food supply, we determined whether commercial agriculture seeds of maize or corn Zea mays L., barley Hordeum vulgare L., safflower Carthamus tinctorius L. and rice Oryza sativa L. are digested or pass viably through the digestive tract, or are transported externally, by captive mallard ducks Anas platyrhynchos L., ring-necked pheasants Phasianus colchicus L., red-winged blackbirds Agelaius phoeniceus (L.) and rock pigeons Columba livia Gmelin (with the exception of whole maize seeds which were too large to feed to the blackbirds). These crop seeds, whether free-fed or force-fed, did not pass through the digestive tract of these bird species. The birds nonetheless did retain viable seeds in the esophagus/crop and gizzard for several hours. For example, after foraging for 6 h, mallards had retained an average of 228 +/- 112 barley seeds and pheasants 192 +/- 78 in the esophagus/crop, and their germination rates were 93 and 50%, respectively. Birds externally transported seeds away from the feeding location, but in only four instances were seeds found attached to their muddy feet or legs and in no case to feathers. Risk of such crop seeds germinating, establishing and reproducing off site after transport by a bird (externally or internally) or movement of a carcass by a predator, will depend greatly on the crop and bird species, location, environmental conditions (including soil characteristics), timing, and seed condition.
Collapse
Affiliation(s)
- John L Cummings
- U.S. Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center, 4101 LaPorte Avenue, Fort Collins, CO 80521, USA.
| | | | | | | | | | | |
Collapse
|
27
|
Spök A, Twyman RM, Fischer R, Ma JK, Sparrow PA. Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends Biotechnol 2008; 26:506-17. [DOI: 10.1016/j.tibtech.2008.05.007] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2008] [Revised: 05/15/2008] [Accepted: 05/16/2008] [Indexed: 12/01/2022]
|
28
|
Pujol M, Gavilondo J, Ayala M, Rodríguez M, González EM, Pérez L. Fighting cancer with plant-expressed pharmaceuticals. Trends Biotechnol 2007; 25:455-9. [PMID: 17869360 DOI: 10.1016/j.tibtech.2007.09.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2007] [Revised: 06/18/2007] [Accepted: 09/03/2007] [Indexed: 11/24/2022]
Abstract
Cancer is one of the most prevalent diseases worldwide, which explains why biological therapies for cancer are forecast to make up 35% of total recombinant pharmaceuticals by 2010. Because of the high demand for cancer drugs, the need to lower production costs and the constraints of present production technologies for recombinant pharmaceuticals (such as the difficulties involved in culturing bacteria, yeast and mammalian cells), attention has recently been focused on recombinant expression of pharmaceutical anti-cancer proteins in plants. This review aims to provide an update on the most recent publications about anti-cancer recombinant pharmaceuticals expressed in plants, as well as on the relevant technical issues, potential and prospects of this emerging production system.
Collapse
Affiliation(s)
- Merardo Pujol
- Plant Division, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, C.P. 10600, Havana, Cuba.
| | | | | | | | | | | |
Collapse
|